Cimerli

Cimerli is a prescription biosimilar medicine manufactured by Coherus BioSciences containing Ranibizumab as the active substance. As a biosimilar, it is approved on the basis of demonstrated comparability to its reference biological product in terms of quality, safety, and efficacy, and is used as part of evidence-based medical care for the indications described in the approved product labeling.
This product is supplied as Pre-filled Syringe / Vial (Solution for Intravitreal Injection) at a strength of 6 mg/mL (0.05 mL / 0.165 mL), packaged in 1s, and is intended for administration by, or under the supervision of, a qualified healthcare professional. Dosing, route of administration, and treatment duration should follow the official prescribing information and applicable clinical guidelines for the patient population being treated.
Cimerli is manufactured under strict biopharmaceutical quality and regulatory standards, ensuring consistent potency, purity, and stability across batches. Each lot is subjected to comprehensive quality control testing in line with international regulatory expectations to support reliable performance in clinical use.
Healthcare providers should review patient history, contraindications, and concurrent medications before use, and counsel patients on expected benefits, possible adverse reactions, and important warnings as outlined in the approved labeling. Storage and handling instructions provided by the manufacturer must be followed to maintain product integrity until the time of administration.
Buy Cimerli online from Apple Globalcare for reliable access to quality biosimilar pharmaceutical products with worldwide delivery.